Deutsche Bank cuts Evonik to “hold,” trims target to €16 on weaker outlook

Deutsche Bank downgraded Evonik Industries (ETR:EVKn) to "hold" from "buy" and reduced its price target to €16 from €22, citing significantly weaker earnings expectations and governance concerns. The bank revised down its 2025 and 2026 EBITDA forecasts, which are now below consensus, and anticipates the company will cut its 2025 guidance, suggesting no immediate buying opportunity due to ongoing risks and questions regarding the credibility of mid-term targets following the CFO's departure.

Analysis

Deutsche Bank has downgraded Evonik Industries (ETR:EVKn) to “hold” from “buy” and materially reduced its price target to €16 from €22, signaling significant headwinds. The downgrade is predicated on weakening earnings expectations due to both cyclical and structural pressures, with the bank forecasting a normalization in previously over-earning business segments. Consequently, Deutsche Bank has revised its EBITDA forecasts downward, projecting H2 2025 results to be 1% lower and full-year 2026 to be 12% lower than previous estimates, placing their outlook 4% and 12% below consensus, respectively. A key concern is the potential for a guidance cut, as the bank notes Evonik’s 2025 EBITDA forecast is 16% above its 2023 trough, a stark contrast to sector peers who are trending 10% below. Compounding this financial outlook are governance issues, sparked by the recent departure of the CFO, which raises questions about the credibility of mid-term targets. This skepticism is reflected in the bank's own projections, which fall approximately 25% short of Evonik’s 2027 EBITDA goal, suggesting underlying risks persist beyond the near term.

Key Decisions for Investors

• Given the downgrade to 'hold' and a new price target of €16 offering minimal upside from its recent close, investors should reassess the stock's potential for near-term capital appreciation.
• Investors should anticipate a downward revision of the company's 2025 guidance, which could serve as a negative catalyst for the stock, as analyst estimates are already significantly below consensus.
• Exercise heightened scrutiny over the company's management and strategy, as the recent CFO departure has introduced material uncertainty regarding governance and the credibility of its mid-term financial targets.
• Refrain from viewing any potential price weakness following a guidance cut as a buying opportunity, as the analyst's note explicitly warns of persistent structural and cyclical risks extending into 2026.